Researchers at the University of the Balearic Islands (UIB) and the Health Service (IBSALUT) have patented the use of phytate and its combination with B6 vitameros to prevent the development of complications associated with diabetes mellitus.
This patent is the first that has been done jointly between both institutions within the framework of the Institute of Health Research (IDISBA).
The patent, which has recently been transferred to the Devicare company, has been graduated in the international arena, as explained from the UIB.Diabetic patients have abnormally high blood glucose values, and this excess induces the development of diabetes pathologies, such as neuropathy, nephropathy, atherosclerosis or vascular calcification.
At the same time, as needed from the university, this excess blood glucose has also been indicated as responsible for the increase in neurodegenerative diseases, such as Alzheimer's and Parkinson's Parkinson, in diabetic people.
The triggering factor of these pathologies in diabetics is the reaction of excess sugar on the organism proteins and the consequent formation of the final products of glycation or AGE, which induce structural and functional changes in the proteins on which they are formed.
The formation of the AGEs becomes through oxidative processes, so the use of compounds with antioxidant capacity prevents their formation and the development of diabetes associated with diabetes.
In the study of the UIB and Hospital researchers Son LLàtzer, the administration of phytate to 40 patients with type 2 diabetes mellitus implied a remarkable decrease in the amount of circulating AGE, as well as in the typical indicators of glycation measurementand oxidative stress.
Therefore, they ensure that the patent protects the use of phytate for the prevention of AGE formation and the pathologies associated with diabetes, individually or in combination with other natural compounds, such as pyridoxamine, a derivative of vitaminB6.
